Idelalisib in combination with ofatumumab improves progression-free survival in previously-treated patients with chronic lymphocytic leukaemia

Posted: 1 June 2015 |

Results from a study of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia have been announced…

Gilead Sciences has announced results from the Phase 3 clinical Study 119 of an investigational use of idelalisib in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukaemia (CLL).


In Study 119, there was a 73% reduction in the risk of disease progression or death in patients receiving idelalisib in combination with ofatumumab compared to ofatumumab alone. Detailed results will be presented today during a poster session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract #7023).

Idelalisib regimen significantly improved progression free survival in patients with CLL

“The data reported today reinforce prior results showing that idelalisib, here in combination with the anti-CD20 monoclonal antibody ofatumumab, not only significantly improved overall and lymph node response rates, but more importantly progression-free survival in patients with previously treated CLL,” said Jeffrey A. Jones, MD, MPH, Associate Professor of Medicine, Division of Haematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).  “Importantly, these improvements were also observed in patients with genetic features typically associated with poor prognosis.”

Study 119 was a randomised, controlled, open-label Phase 3 study evaluating the efficacy and safety of idelalisib in combination with ofatumumab.  The study enrolled 261 adult patients with previously treated CLL whose disease had progressed less than 24 months following completion of prior therapy, and had not previously been refractory to ofatumumab. 

The primary endpoint for Study 119 was progression-free survival (PFS), defined as the time from randomisation to definitive disease progression or death assessed by an independent review committee. Median PFS in the idelalisib/ofatumumab arm was 16.3 months, compared to 8.0 months in the ofatumumab monotherapy arm.

Idelalisib regimen demonstrated statistically significant improvements in lymph node response rate

Statistically significant improvements were also observed for overall response rate and lymph node response rate.  Median PFS in the approximately 40% of patients with 17p deletion or TP53 mutation was 13.7 months vs. 5.8 months.  A statistically significant difference was not achieved in median overall survival (20.9 months vs. 19.4 months).

The safety profile of idelalisib was similar to prior studies in previously-treated patients with CLL. 

Based on the Study 119 trial results, Gilead has filed a supplemental New Drug Application (sNDA) with the US Food and Drug Administration to include data from this study in the US label.  Gilead plans to submit a supplemental filing to the European Medicines Agency later this year.

“Idelalisib has now demonstrated strong efficacy in two randomized Phase 3 studies among previously treated CLL patients,” said Norbert Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer.  “We continue to explore the clinical profile of idelalisib in combination with both standard and novel treatment regimens, including seven ongoing or completed Phase 3 clinical trials for B-cell malignancies.”

Related organisations

Related diseases & conditions

Comments are closed.

Send this to a friend